RxDoctor Payments Data

Taryn Turner, DO

Nephrology · Granbury, TXNPI 1184724122

Payments from drug & device makers

$7,410in general payments, 2019–2025

Across 86 payments — averaging $86.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$5K
  • AstraZeneca$489
  • Amgen$452
  • Otsuka America Pharmaceutical, Inc.$301
  • Calliditas Therapeutics US Inc.$267
  • Bayer$252
  • plus $808 from 11 others

What the payments were for

  • Travel & lodging$4,43060%
  • Food & beverage$2,84138%
  • Education$1392%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,410 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$352,576
Medicare patients
374
Services billed
4,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide68$189,106
FarxigaDapagliflozin Propanediol136$146,513
KerendiaFinerenone110$145,141
JardianceEmpagliflozin126$139,532
AuryxiaFerric Citrate28$80,620
LokelmaSodium Zirconium Cyclosilicate57$55,724
XphozahTenapanor Hcl14$46,203
RayaldeeCalcifediol51$43,681
VeltassaPatiromer Calcium Sorbitex30$39,796
JanuviaSitagliptin Phosphate36$31,256
Lanthanum Carbonate33$27,230
Sevelamer Carbonate121$20,172
EliquisApixaban22$14,682
ProsolParenteral Amino Acid 20% No.136$13,418
Cinacalcet Hcl37$8,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$489$202,237193 claims
Fresenius USA Marketing, Inc.Velphoro$4,842$189,10668 claims
BayerKerendia$252$145,141110 claims
Boehringer IngelheimJardiance$44$139,532126 claims
Akebia Therapeutics IncAuryxia$42$80,62028 claims
OPKO Pharmaceuticals, LLCRayaldee$207$43,68151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →